O le urticaria, e masani ona taʻua o le maʻi fulafula, o se maʻi e tupu i le paʻu e iloga i le foliga mai o ni maʻila mūmū e mageso ma e oso aʻe i luga o le paʻu.
O le pathophysiology o le urticaria e aofia ai le faamatuu atu o le histamine ma isi vailaau e faaōleōle ai mai sela o le tino, o sela ia e puipuia ai le tino mai faamaʻi o loo maua i le paʻu ma isi vaega o le tino.
I le urticaria faaumiumi, e faamatuu mai ai le histamine ma isi vailaau e māfua mai i le allergic reaction i se mea e māfua ai le allergy, e pei o meaʻai, fualaau, po o le ūina e iniseti.
O le iʻuga, e lē toe maua ai ni sela o le tino, ma e faamatuu mai ai le histamine ma isi vailaau e mafai ona faaleagaina ai alātoto, ma maua ai ni sela e taʻu o wheals.
I le urticaria faaumiumi, e lē masani ona iloa le pogai, ae e manatu e fesootaʻi atu i se faiga e māfua mai i le tino o le tagata.
I lenei tulaga, e maua ai e le tino ni autoantibodies e taulaʻi atu i le IgE receptor (FcεRI) i luga o sela o le mast, ma mafua ai ona faʻagaoioia ma faʻasaʻoloto le histamine ma isi mediators.
I le urticaria faaumiumi ma le urticaria faaumiumi, e faapogaia ai e le histamine ma isi vailaau e pei o le fulafula, mūmū, ma le mageso.
O le togafitiga e masani lava ona aofia ai le faaaogāina o vailaau e tetee atu i le histamine e taofia ai aafiaga o le histamine ma faaitiitia ai āuga.
I tulaga ogaoga, e mafai ona faaaogā isi vailaau e pei o corticosteroids po o le omalizumab e pulea ai le maʻi.
Wahlgren CF: Pathophysiology of itching in urticaria and atopic dermatitis. Allergy. 1992, 47 (2 Pt 1): 65-75.
Raap U, Liekenbröcker T, Wieczorek D, Kapp A, Wedi B: [New therapeutic strategies for the different subtypes of urticaria]. Hautarzt. 2004, 55 (4): 361-6.
[Recommendations for the diagnosis and treatment of urticaria in children]. Arch Argent Pediatr. 2021, 119 (2): S54-S66.
Brzoza Z, Grzeszczak W, Rogala B, Trautsolt W, Moczulski D: Possible contribution of chemokine receptor CCR2 and CCR5 polymorphisms in the pathogenesis of chronic spontaneous autoreactive urticaria. Allergol Immunopathol (Madr). , 42 (4): 302-6.
Sweeney TM, Dexter WW: Cholinergic urticaria in a jogger: ruling out exercise-induced anaphylaxis. Phys Sportsmed. 2003, 31 (6): 32-6.
['Faamatalaga: faafomaʻi']
['O lenei upega tafaʻilagi ua saunia mo na o le aʻoaʻoina ma le faailoaina atu o faamatalaga, ae e lē o se fautuaga faafomaʻi po o se auaunaga faapolofesa.']
['E lē tatau ona faaaogā faamatalaga o loo maua mai ai e iloa ai po o le ā le maʻi o loo aafia ai, ma e tatau i ē o loo saʻili mo ni fautuaga faafomaʻi, ona talanoa atu i se fomaʻi ua agavaa.']
['Faamolemole ia mātau, o le neural net lea e maua ai tali i fesili, e lē saʻo pe a oo i fuainumera.']
["Ia saʻili i taimi uma le fautuaga a lau fomaʻi poʻo se isi fomaʻi agavaa e tusa ai ma se maʻi. Aua neʻi e le amanaʻia fautuaga faʻapitoa a fomaʻi pe tuai ona saili ona o se mea na e faitauina i luga o lenei upega tafailagi. Afai e te manatu e ono i ai sau faʻalavelave faʻafuaseʻi, valaʻau le 911 pe alu i le potu lata ane faʻafuaseʻi. E leai se fomaʻi-tagata gasegase sootaga e faia e lenei 'upega tafaʻilagi poʻo lona faʻaaogaina. E leai se BioMedLib poʻo ana tagata faigaluega, poʻo se tasi e fesoasoani i lenei' upega tafaʻilagi, faia ni faʻamatalaga, faʻaalia pe faʻaalia, e tusa ai ma faʻamatalaga o loʻo tuʻuina atu iinei poʻo lona faʻaaogaina."]
['Faʻasalaga: puletaofia']
['O le Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (le DMCA) e maua ai le avanoa mo tagata e umia le puletaofia o loʻo talitonu o mea o loʻo aliali mai i luga o le Initaneti e solia ai a latou aia tatau i lalo o le tulafono a le US copyright. ']
['Afai e te talitonu ma le talitonuga lelei e faapea o so o se mataupu po o meafaitino ua maua e fesootai ma lo tatou website po o auaunaga solia lou puletaofia, e mafai ona e (po o lou sooupu) auina atu i tatou se faasilasilaga talosagaina e faapea o le mataupu po o meafaitino e aveesea, po o le avanoa i ai poloka. ']
['E tatau ona auina atu faasilasilaga i se faiga tusitusia e ala i imeli (tagai i le vaega o le "Contact" mo le tuatusi imeli). ']
['O le DMCA e manaʻomia ai lau faʻasilasilaga o le faʻaleagaina o le puletaofia e aofia ai faʻamatalaga nei: (1) faʻamatalaga o le galuega faʻatagaina o loʻo faʻatatau i le faʻaleagaina o le puletaofia; (2) faʻamatalaga o le mea e ono solia ai ma faʻamatalaga lava e faʻatagaina ai matou ona maua le anotusi; (3) faʻamatalaga faʻafesoʻotaʻi mo oe, e aofia ai lau tuatusi, numera telefoni ma tuatusi imeli; (4) o se faʻamatalaga mai ia te oe o loʻo ia te oe le talitonuga lelei o le anotusi i le auala na faitio ai e le faʻatagaina e le pule o le puletaofia, poʻo lana sooupu, poʻo le faʻatinoina o soʻo se tulafono; ']
['(5) o se faamatalaga mai iā te oe, ua sainia i lalo o le faasalaga o le pepelo, e faapea o faamatalaga o loo i le faasilasilaga e saʻo ma e iai lau pule e faamalosia ai le aiā tatau lea o loo faapea mai ua solia; ']
['ma le (6) saini faaletino po o saini faaeletoroni a lē e ana le aiā tatau po o se tagata ua faatagaina e galue e fai ma sui o lē e ana le aiā tatau. ']
['Afai e lē o aofia uma faamatalaga o loo i luga, e ono faatuai ai ona iloilo lau faitioga.']
['Faafesootaʻi']
['Faamolemole lafo mai se imeli i so o se fesili / fautuaga.']
What is pathophysiology of urticaria?
Urticaria, commonly known as hives, is a skin condition characterized by the appearance of itchy, raised, red welts (wheals) on the skin.
The pathophysiology of urticaria involves the release of histamine and other inflammatory mediators from mast cells, which are immune cells found in the skin and other tissues.
In acute urticaria, the release of histamine and other mediators is triggered by an allergic reaction to a specific allergen, such as food, medication, or insect sting.
This causes the mast cells to degranulate, releasing histamine and other mediators that cause blood vessels to become leaky, leading to the formation of wheals.
In chronic urticaria, the cause is often unknown, but it is thought to be related to an autoimmune mechanism.
In this case, the body produces autoantibodies that target the high-affinity IgE receptor (FcεRI) on mast cells, leading to their activation and the release of histamine and other mediators.
In both acute and chronic urticaria, the release of histamine and other mediators leads to the characteristic symptoms of itching, redness, and swelling.
Treatment typically involves the use of antihistamines to block the effects of histamine and reduce symptoms.
In severe cases, other medications such as corticosteroids or omalizumab may be used to control the condition.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['E tusa o le']
['E faaaogā e le BioMedLib ni komepiuta (machine-learning algorithms) e faia ai ni fesili ma ni tali.']
['E amata i le 35 miliona lomiga faafomaʻi o le PubMed/Medline.']
['Tagaʻi i le "Faamatalaga" ma le "Faamatalaga".']
